| 10.42 0.23 (2.26%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.48 | 1-year : | 14.56 |
| Resists | First : | 11.54 | Second : | 12.47 |
| Pivot price | 10.54  |
|||
| Supports | First : | 10.03 | Second : | 8.35 |
| MAs | MA(5) : | 10.26 |
MA(20) : | 10.64 |
| MA(100) : | 11.02 |
MA(250) : | 10.78 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 19.4 |
D(3) : | 15.3 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 13.15 | Low : | 6.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMTX ] has closed above bottom band by 38.6%. Bollinger Bands are 34.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.62 - 10.67 | 10.67 - 10.73 |
| Low: | 10.09 - 10.17 | 10.17 - 10.24 |
| Close: | 10.31 - 10.42 | 10.42 - 10.52 |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Mon, 22 Apr 2024
(IMTX) Investment Analysis - News Stock Traders Daily
Tue, 16 Apr 2024
Immatics (NASDAQ:IMTX) Short Interest Update - MarketBeat
Thu, 28 Mar 2024
Immatics N.V.'s (NASDAQ:IMTX) institutional investors lost 7.9% last week but have benefitted from longer-term gains - Simply Wall St
Thu, 21 Mar 2024
Immatics N.V. Showcases Clinical Strides and Fiscal Health - TipRanks.com - TipRanks
Thu, 21 Mar 2024
Immatics Announces Full Year 2023 Financial Results and Corporate Update - GlobeNewswire
Fri, 15 Mar 2024
With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 25.6 (%) |
| Held by Institutions | 51.3 (%) |
| Shares Short | 8,910 (K) |
| Shares Short P.Month | 8,030 (K) |
| EPS | -1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.66 |
| Profit Margin | -179.7 % |
| Operating Margin | -174.1 % |
| Return on Assets (ttm) | -13.9 % |
| Return on Equity (ttm) | -44.3 % |
| Qtrly Rev. Growth | -57.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.52 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 18 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -8.15 |
| PEG Ratio | -0.6 |
| Price to Book value | 3.91 |
| Price to Sales | 19.87 |
| Price to Cash Flow | 58.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|